Home › Trials › NCT06949865
Clinical trial Recruiting at 1 site Observational Ages 50 to 75

Using AI to improve the levodopa challenge test for Parkinson's disease diagnosis

Official title: Clinical Research on Optimization of Acute Levodopa Challenge Test and Exploration of New Motor Paradigm Based on the Integration of Perception Technology and Artificial Intelligence

Run by Beijing Tiantan Hospital · NCT06949865 · Data updated 2026-11-12

This study is testing a new way to diagnose Parkinson's disease using artificial intelligence and video recordings to see if it can improve the accuracy of the levodopa challenge test.

Quick facts

Study typeObservational
Ages50 Years to 75 Years
SexAll
Enrollment2000 (estimated)
SponsorBeijing Tiantan Hospital
Academic / other
Locations1 site (Beijing)
StatusRecruiting
StartedMay 28, 2024
Main results expectedDecember 31, 2026
Study endsDecember 31, 2026
Registry record updatedApril 29, 2025
Trial IDNCT06949865 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include individuals aged 50-75 with confirmed Parkinson's disease, multiple system atrophy, or progressive supranuclear palsy.

Probably not a fit

Patients outside the age range of 50-75 or those without a confirmed diagnosis of the specified conditions may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates a new quantitative method for diagnosing Parkinson's disease and other atypical parkinsonism by integrating motor paradigms with artificial intelligence and perception technologies. It aims to identify diagnostic cut-off values for various forms of parkinsonism and explore digital biomarkers for early and differential diagnosis. The approach combines traditional assessments with an acute levodopa challenge test and video recordings to enhance diagnostic accuracy.

Why it matters

Potential benefit: If successful, this study could lead to more accurate and earlier diagnoses of Parkinson's disease and related conditions.

How similar studies have gone: Other studies have shown promise in using AI and digital biomarkers for diagnosing Parkinson's disease, indicating that this approach may be viable.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Parkinson's disease (PD) group: 1. Patients with confirmed Parkinson's disease diagnosed based on the 2015 International Movement Disorder Society (MDS) Parkinson's Disease Diagnostic Criteria; 2. Patients with early-stage PD meet the Hoehn-Yahr score ≤ 2.5 points, and patients with intermediate and advanced PD meet the Hoehn-Yahr score of 2.5-5 points; 3. Subjects are 50-75 years old (including boundary values), gender is not limited; 4. Agree to undergo study-related examination evaluation and sign informed consent.
2. Multiple system atrophy (MSA) group : 1. Patients with confirmed or probable MSA diagnosed based on the diagnostic criteria for MSA published by the International Movement Disorder Society (MDS) in 2022 ;2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.
3. Progressive supranuclear palsy (PSP) group: 1. Patients with confirmed or probable PSP diagnosed based on the diagnostic criteria of the 2017 International Movement Disorder Association PSP Collaborative Group; 2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.
4. Vascular parkinsonism (VP) group: 1. In line with the diagnostic recommendations of vascular parkinsonism in accordance with the 2004 International Association for Movement Disorders and the 2017 Chinese expert consensus; 2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.
5. Drug-induced parkinsonism (DIP) group: 1. Parkinsonism; 2. Drug history, the appearance of symptoms is related to specific drugs; 3. Symptoms are reversible, and the symptoms are reduced or disappeared when the corresponding drugs are reduced; 4. Rule out other causes; 5. Subjects are 50-75 years old (including boundary values), gender is not limited; 6. Agree to undergo study-related examination evaluation and sign informed consent.
6. Corticobasal degeneration (CBD) group: 1. Diagnosis of probable or probable CBD based on the 2019 Chinese diagnostic criteria for corticobasal degeneration; 2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.
7. Dementia with Lewy Bodies (DLB) Group: 1. Diagnosed as probable or possible DLB based on the 2017 international DLB diagnostic criteria and the 2021 Chinese DLB diagnostic criteria. 2. Exhibits symptoms of Parkinsonism. 3. Subjects are aged 50-75 years (inclusive), with no gender restriction. 4. Agree to undergo study-related assessments and evaluations and signs the informed consent form.

Exclusion Criteria:

1. Cognitive dysfunction, unable to complete the study (MMSE \< 23)
2. Inability to tolerate levodopa shock test
3. Patients with failure of important organs (heart, lung, liver, kidney, etc.), malignant tumors, unstable conditions and other serious internal diseases
4. Those with serious behavioral problems or mental disorders
5. Inability to sign informed consent
6. Other conditions that are considered unsuitable by the investigator to participate in this study.

Where it's running

  • Beijing Tiantan Hospital, Affiliated to Capital Medical University
    Beijing, China     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Vascular Parkinsonism 3Corticobasal Degeneration (CBD) 5Parkinson Disease (PD) 44Progressive Supranuclear Palsy(PSP) 7Multiple System Atrophy (MSA) 7Beijing Tiantan Hospital 169
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.